title: Commonality of the IL-4/IL-13 pathway in atopic diseases.
abstract: Allergy results from an aberrant Type 2 inflammatory response, triggered by a wide range of environmental antigens (allergens) that lead to various immune responses, culminating in the production of immunoglobulin E (IgE). Two key cytokines, interleukin (IL)-4 and IL-13, are critical to the induction and perpetuation of the Type 2 response, and have been implicated in multiple atopic diseases. Area covered: This review summarizes recent milestone developments that have elucidated components of the pathogenesis of atopic diseases such as atopic dermatitis (AD), asthma, and chronic sinusitis with nasal polyposis (CSwNP). Expert commentary: Several therapeutic agents that selectively target potentiators of the Type 2 pathway have shown efficacy in one or more of these atopic diseases, but few agents have proven to be broadly applicable across all three atopic diseases. Dupilumab, a human monoclonal antibody that simultaneously inhibits signaling of IL-4 and IL-13, has demonstrated significant clinical efficacy in AD, asthma, and CSwNP. The fact that these diseases often occur as comorbidities and respond to the same therapy suggests that there is a common underlying pathogenic pathway, and that IL-4 and IL-13 cytokines are central to regulating the pathogenesis of these atopic diseases.
authors.affiliation: a Clinical Sciences , Regeneron Pharmaceuticals, Inc. , Tarrytown , New York , USA.
authors.forename: Namita A
authors.initials: NA
authors.lastname: Gandhi
authors.affiliation: b Research and Development , Sanofi, Bridgewater , New Jersey , USA.
authors.forename: Gianluca
authors.initials: G
authors.lastname: Pirozzi
authors.affiliation: c Project Direction , Regeneron Pharmaceuticals, Inc. , Tarrytown , New York , USA.
authors.forename: Neil M H
authors.initials: NMH
authors.lastname: Graham
mesh_terms: D000485:Allergens / Q000276:immunology; D001249:Asthma / Q000276:immunology*; D002908:Chronic Disease; D003876:Dermatitis, Atopic / Q000276:immunology*; D006801:Humans; D018793:Interleukin-13 / Q000378:metabolism*; D015847:Interleukin-4 / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D009298:Nasal Polyps / Q000276:immunology*; D015398:Signal Transduction; D012852:Sinusitis / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology*
chemical_list: D000485:Allergens; D018793:Interleukin-13; D015847:Interleukin-4
keywords: Type 2 pathway; asthma; atopic dermatitis; dupilumab; interleukin-13; interleukin-4; lebrikizumab; nasal polyposis; tralokinumab